HP DNA

HP DNAHighly Polymerized Deoxyribonucleic Acid

Definition

Marine Biopolymer characterized by

Its source

Its special method of extraction

Its determined physico-chimical properties

Highly Polymerized Deoxyribonucleic Acid

HP DNA

Origin

Natural hydrosoluble substance extracted from the milt of wild salmon

By non-denaturating technology

• protecting the superstructure of polymer

• preserving its physiological activity


HP DNA

Aspect

White-cream fibers measuring several centimeters


HP DNA

Solubility

Relatively soluble in water

Making a gel with low concentration (1.0 to 3.0 %)

insoluble in

• alcohol

• ethanol

• the other oganic solvents


HP DNA

Metabolism

• half-life of 72 hours at rat

• elimination after 96 hours:fecal (62,8 %) and urinary (19,4 %)

• hepatic degradation in mononucleotides

• biliary elimination

• the intestine seems to retain polymerized parts of DNA and to be rapidly saturated in part of low molecular weight

• the lymphatic tissue seems to accumulate polymerized parts of DNA then to release them rapidly in venous blood


HP DNA

Followed by laboratory Sterlin-Winthrop from 1985 and 1990

• administration almost without secondary effects

• excellent clinical tolerance (superior to 90 %)

Pharmacovigilance


HP DNA

• It retards and diminishes the formation of dienes conjuges (joined paired),notably by its antiradical activity vis-à-vis the hydroxyl radical (OH°–)

Antioxidant Properties (1)

•Highly Polymerized Deoxyribonucleic Acid

HP DNA

25

5865

7278

85

0

10

20

30

40

50

60

70

80

90

% of inhibition of DMPO-OH signal

0,4 0,8 1,2 1,6 2 2,4

HPDR concentration (mg/ml)

HPDR inhibition of free radical formation

HPDR

•The capturing of this highly reactive radical by HP DNA accompanies the formation of a stable product, the 8-hydroxy-guanosine (8-OHDG), and avoids the formation of a new free radical and thus terminates the process of peroxydation.

=> HP DNA protects the cells against extra cellular oxidative aggressions.

Antioxidant Properties (2)


HP DNA

Antioxidant Properties (3)Highly Polymerized Deoxyribonucleic Acid

HP DNA

• protector effect against lipoperoxydation

0

1

2

3

4

5

6Mesurement of

conjugated dienes OD 234 nm

0 2 4 6 8

Days

Arachidonic Acid oxidation with and without HPDR

Arachidonic Acid 2,5.10-3 M

Arachidonic Acid / HPDR 90µg/ml

Antioxidant Properties (4)Highly Polymerized Deoxyribonucleic Acid

HP DNA

Inhibition of lipid peroxydation by the association of vit E + HPDR in rat hepatocytes overloaded by iron

Vit E (250.10 -6 M) HPDR (mg/ml)

250.10 -6M 1mg/ml 2 mg/ml 4 mg/ml

Vit E (250.10-6 M+ HPDR (mg/ml)

1 mg/ml 2 mg/ml 4 mg/ml

0

10

20

30

40

50

60

70

80

90

100

Inhibition (%) of productionof free malonic dialdehyde

Open clinical study : HP DNA 8OO mg/j during 30 days• 44 asthenic adults (having no less than 15 of the 60 asthenia symptoms present) compared to 32 normal adults (having less than 15 of the 60 asthenia symptoms present)• 62.7 % of the physical asthenic symptoms • 40 % of the mental asthenic symptoms• The scores observed in the treated asthenic patients directly approached those patients seen as normal• 58 of 60 of asthenia symptoms• many of the most debilitating symptoms • action on asthenia by HP DNA globally is positive in 52.4% of the cases

Anti-asthenia effect(1)

•Highly Polymerized Deoxyribonucleic AcidHP DNA

Open multi-centered study: HP DNA 800 mg/day during 15days• 688 adults (445 women and 243 men) •spontaneous asthenia showed during the interrogation/isolated or associated with a non evolutionary benign organic pathology

Treatment by HP DNA: • Behaviour Rating Scale (61 criteria) - 64.5 % for physical asthenia, - 57.0 % for mental asthenia• improvements more intensively marked when more severe symptoms • global efficacy of the treatment evaluated by researchers in 79.1% of the cases

Anti-asthenia effect (2)


HP DNA

Amélioration de l’asthénie physique



63

57

46

55

46

62,5

39

0

10

20

30

40

50

60

70Improvment (%)

Effect of the HPDR on physical symptoms (688 people - average age = 44 years) after 15 days (daily dose = 800 mg/day of HPDR)

Improvement of psychic asthenia

Anti-asthenia effect (4)•Highly Polymerized Deoxyribonucleic Acid

HP DNA

32

54 54

47 4550

0

10

20

30

40

50

60Improvment (%)

Improvment on mental symptoms (688 people - average age = 44 years)with 800 mg/day of HPDR during 15 days

Open study • HP DNA 400 mg/day +ascorbic acid 1 g/day during 15 days• 6876 patients Patients did not receive another anti-asthenia treatment (70 % of cases)• fatigue at night (a reduction of more than 50% of the intense symptoms) in 82.5 % of cases • fatigue in the morning in 82.9 % of cases• difficulty concentrating in 76.9 % of cases• trouble sleeping in 75 % of cases• trouble with appetite in 80 % of cases



HP DNA



HP DNA

82,5

20

82,9

24,3

76,9

20,5

75

25,7

80

33,9

0

10

20

30

40

50

60

70

80

90

% studied people

Evening

tiredness

Tiredness upon

waking up

Difficulty

concentrating

Sleep disorders Appetite

disorders

Effect of HPDR - Survey on physical fatigue (1000 doctors)

400 mg/day of HPDR + 1 g/day of vitamin C during 15 days

Improvment > 50 %

Recovery

Open clinical trial : ADN-HP 800 mg/day during 1 month• 24 persons of more than 50 years with asthenia of which 16 had anorexia and 8 were chronic alcoholics



HP DNA

Treatment by HP DNA• patients general state in 70 % of cases and mental state in 63% of cases



70

63

58

60

62

64

66

68

70

GeneralImprovment

Improvment inpsychological

behaviour

Effect of HPDR on the elderly people(> 50 years) with 800 mg/day of HPDR after 1 month

Improvment (in %)

Multicentric clinical study, in a double blind• 116 patients suffering from chronic spinal problems (for a period of more than 1 month)• HP DNA 800 mg/day during 30 days versus placebo

Treatement by HP DNA • 43.6 % intensity of the pain, quantified on the numeric scale of Huskinson (versus 25.4 % with placebo) • 32.6 % degree of functional discomfort (handicap) (versus 25.4 % with placebo) • 43. 3 % importance of the limitation of passive mobilization of the spine (versus 26.9 % with placebo)

Effect on basic arthralgies (1)


HP DNA

Effect on basic arthralgies (2)


HP DNA

43,6

25,4

32,7

25,5

43,3

26,9

39,6

25,5

0

5

10

15

20

25

30

35

40

45

(%)

Reduction in pain Reduction in thedegree of

functionaldifficulty

Increase invertebral column

mobility

Overallimprovment in

general condition

Effect of the HPDR on back pain (116 people - average age = 42 years) after 30 days (daily dose of HPDR = 1g/day)

HPDR

Placebo

Open study• 2960 persons affected by arthrosis, with an average age of 61.1 years old• ADN-HP 400 mg/day + complex of vitamins (B + E)• during 1 or 2 months

Treatment by HP DNA• at the end of the first month of treatment: pains in 89.5 % of cases – 21 % were completely relieved – 68.5 % were partially relieved physical performance in 83.6 % of cases

Chondrostimulating activity (1)


HP DNA



HP DNA

21

68,5

83,6

0

10

20

30

40

50

60

70

80

90

% people studied

Completely relieved

pain

Partially relieved pain Improved physical

performance

Effect of HPDR on osteoarthritis

(2960 people - average age = 61 years)with 400 mg/j of HPDR + vit B + vit E after 30 days

In double blind study • 67 persons affected by arthrosis with average disability of the knees and hips• HP DNA 400 mg/day + complex of vitamins (B + E)• versus diclofénac (anti-inflamatory, non-steroid) • during 42 days



HP DNA

Treatment by HP DNA • 39 % pain (versus 35 % with diclofénac)



HP DNA

13

27

39

35

0

5

10

15

20

25

30

35

40% of reduction in

pain

J21 (T0 + 21 days) J42 (T0 + 42 days)

Effect of HPDR on knee or hip osteoarthritis (67 people) of 400 mg/day of HPDR + vit E + vit B after 42 days

HPDR

Diclofénac

Treatment by HP DNA• 16.1 % degree of impotence (versus 26,1 % with diclofénac)



HP DNA

1

15,2 16,1

26,1

0

5

10

15

20

25

30%of reduction of infirmity degree

J21 (T0 + 21 days) J42 (T0 + 42 days)

Effect of HPDR on knee or hip osteoathritis (67 people) with 400 mg/day of HPDR + vit B + vit E after 42 days

HPDR

Diclofénac

Study : with a traditional local method• 108 patients affected by periodontal pathology,• HP DNA 1600 mg/day during 3 months

With administration of HP DNA• the index of dental mobility to a high of 45.7% • ………………………… to a low of 22.5%

Consolidation of dental joints (1)


HP DNA

Success treatment for :• 56 % of patients treated by HP DNA and local treatment

• 7 % only of patients treated with a traditional local method

Consolidation of dental joints (2)


HP DNA

7

56

23

3

70

39

0

10

20

30

40

50

60

70

% studied people

Treatmentsuccess

Treatmentfailure

Don't know

Effect of HPDR for the treatment of periodontics (gum) with 1600 mg/day of HPDR after 3 months

Review of 108 random observations

Local treatmentHPDR

Study on mice• HP DNA 200mg/day + ascorbic acid 500 mg/day during 5 days => amelioration of a swimming test


HP DNA

Effect on physical performance (1)

Study on dog• HP DNA 400 mg/day ± ascorbic acid 1 g/day• before standard exertion

• 50 % the frequency of heart exertion with HP DNA+ vit. C• the recuperation time after exertion: – 50 % with HP DNA alone – 83 % with HP DNA + vitamin C• elevation of cortisolemie 50 minutes after exertion: – 71% with HP DNA alone – 100 % with HP DNA + vitamin C


HP DNA


Study on men• 30 athletes with an average age of 20 years old• HP DNA 800 mg/day + vitamin C 2000 mg/day during 21 days


HP DNA



HP DNA

Effect on physical performance (4)Effect of the association (1)• recuperation index, calculated by the Ruffier-Dickson Test

80

20

0

10

20

30

40

50

60

70

80

Improvment Discordant results

Effect on recuperation after exercise with 800 mg/day of HPDR + 2000 mg/day of vitamin C during 21 days


HP DNA


Effect of the association (2)• maximum oxygen intake (VO2 max) evaluated using the Cooper test

37,6

37,8

38

38,2

38,4

38,6

38,8

39

39,2

39,4

39,6

Average at T0 Average at T0 + 21days of treatment

Effect on stamina during exerciseHPDR 800 mg/day + vitamin C 2000 mg/day during 21 days

O2 consommation duringeffort (ml/mn/kg)

Double blind study: HP DNA 200 - 600 mg/day versus placebo during 3 months256 children between the ages of 6 and 21 years with average to profound mental defects

The children have benefited by gaining mental age in cases of:• Exogenous defects with an IQ* > 40 • A real age understanding of between 8 and 14 years* intellectual quotient


HP DNARegenerative action on intellectual development in regard to psychomotor and biometrics of subjects with mental defects

In mice without spleens 4 weeks before, when injected intra-peratonial 0.03 to 0.3 g/kg with HP DNA for 10 days

• resistance vis-à-vis a parasitic infection ( time augmented for surveying the animal traits with regard to the evidence)• capacity of the lymphocytes to divide and produce interleukine 2

In vitro, HP DNA exerted a mitogene effect on the splenocytes of naturally immune-depressed mice.


HP DNA

Immunostimulating activity (1)

Study with patients:

• 66 subjects with leucopenia (leucocytes < 3000)

• a treatment with HP DNA (800-1200 mg/day for 3 weeks) was effective in 77% of the cases, and the majority just after the first week of treatment


HP DNA

Immunostimulating activity (2)

In mice, after the realization of experimental wounds, the administration of HP DNA accelerated the cicatrisation:• by proliferative activity • by the number of polypoid epidermal cells

In rats, one hour after the administration of 325 mg/kg of aspirin, the taking of HP DNA (10 to 50 mg/kg per os) • prevented the apparition of gastric ulcers from aspirin


HP DNA

Regenerative action vis-à-vis the cicatriciels process

Survival level after irradiation proportional to polymerization degree of injected heterologous DNA

At rats • 24 hours after a lethal irradiation of 1000 rœntgens after injection of 300 g of HP DNA => definitive survival

At animal, the administration of HP DNA • bone marrow aplasia (anemia and leucopenia) experimental radio-induced • decrease of spermatogenesis secondary to irradiation


HP DNA

Powerful radioprotective activity

=> To stimulate immunity=> To accelerate the cicatrization=> To restore the general state => For physical and psychic asthenia=> To improve cognitive performances • intellectual quotient • memorization=> To improve physical performance • VO2 max • recuperation time=> To treat basic arthralgies and arthrosis=> To reduce the secondary effects of radiotherapy


HP DNA

Potential Applications

HP DNA, a marine DNA highly polymerized with a strong antioxidant power, with potential applications in health…For asthenia, arthrosis, immunodeficiency, troubles of cicatrisation,…


HP DNA

Documents

HP DNA